

Pathophysiology II

Chapter (2): Respiratory Diseases

- Infectious Diseases
 - Sinusitis
 - COVID-19
- Obstructive Lung Diseases
 - Asthma
 - Chronic Obstructive Pulmonary Disease
 - Cystic Fibrosis


- 2. Coronavirus disease 2019 (COVID-19)
- It is an infectious respiratory disease caused by a newly discovered *coronavirus*.
- Most infected people have mild to moderate respiratory illness and recover without requiring special treatment..
- 2019 novel coronavirus (2019-nCoV)
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)





- 2. Coronavirus disease 2019 (COVID-19)
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)











Structure of SARS-CoV-2



2. (COVID-19)

Pathogenesis

A. Virus entry



2. (COVID-19)

- Pathogenesis
- **B.** Immune response

Cytokine storm


ARDS

2. (COVID-19)

Symptoms

Clinical manifestations

Infectious diseases



2. (COVID-19)

Diagnosis

- Symptoms
- PCR
- Serological test
- Treatments
 - Antiviral agents
 - Anti-inflammatory drugs
 - Convalescent plasma
 - Vaccines

| Company | Туре | Doses | Storage |
|----------------------------|---|-------|--|
| Oxford Uni- AstraZeneca | Viral vector (genetically modified virus) | x2 | 2 to 8°C (6 months) |
| Moderna | RNA (part of virus genetic code) | x2 | -25 to -15°C (7 months) |
| Pfizer-BioNTech | RNA | x2 | -80 to -60°C (6 months) |
| Gamaleya (Sputnik V) | Viral vector | x2 | -18.5°C (liquid form) 2 to 8°C (dry form) |
| Sinovac (CoronaVac) | Inactivated virus (weakened virus) | x2 | 2 to 8°C |
| Novavax | Protein-based | x2 | 2 to 8°C |
| Janssen | Viral vector | ×1 | 2 to 8°C (3 months) |


2. (COVID-19)


Diagnosis

- Symptoms
- PCR
- Serological test
- Treatments
 - Antiviral agents
 - Anti-inflammatory drugs
 - Convalescent plasma
 - Vaccines


| Company | Туре | Doses | Storage |
|----------------------------|---|-------|--|
| Oxford Uni- AstraZeneca | Viral vector (genetically modified virus) | x2 | 2 to 8°C (6 months) |
| Moderna | RNA (part of virus genetic code) | x2 | -25 to -15°C (7 months) |
| Pfizer-BioNTech | RNA | x2 | -80 to -60°C (6 months) |
| Gamaleya (Sputnik V) | Viral vector | x2 | -18.5°C (liquid form) 2 to 8°C (dry form) |
| Sinovac (CoronaVac) | Inactivated virus (weakened virus) | x2 | 2 to 8°C |
| Novavax | Protein-based | x2 | 2 to 8°C |
| Janssen | Viral vector | ×1 | 2 to 8°C (3 months) |

- It is a reversible form of obstructive airway disease caused by narrowing of the airways due to bronchospasm, inflammation, and increased airway secretions.
- Bronchial hyperresponsiveness condition
 - Extrinsic, allergic, atopic asthma
 - Intrinsic, non-atopic asthma







- Causes: hyperresponsiveness of bronchial smooth muscles
 - Extrinsic, allergic, atopic asthma
 - Intrinsic, non-atopic asthma




- Pathogenesis
 - Extrinsic, allergic, atopic asthma






- Pathogenesis
 - Intrinsic, non-atopic asthma



1. Bronchial asthma

Symptoms



1. Bronchial asthma


- Diagnosis
 - Symptoms: wheezing
 - Laboratory findings: for allergic asthma
 - Pulmonary functions: spirometer (VC, FVC, FEV1, FEV1/FVC ratio)
 - Airway responsiveness: histamine, cholinergic agonists, cold air

VC: vital capacity, the maximum amount of air can be expelled from the lungs after a maximum inhalation (4L).

FVC: forced vital capacity, the volume of air that can forcibly be blown out after full inspiration (4.5-5L)

FEV1: forced expiratory volume in 1 second, the volume of air that can forcibly be blown out in first 1 second after full inspiration (80% of FVC)





1. Bronchial asthma

- Treatment
- 1. Life style management and education
- **2. Quick-relief medications:** anticholinergic, adrenergic agonists (adrenaline and short acting B2 agonists)


3. Long term medications


- Inhaled corticosteroids
- Long-acting B2 agonists
- Cromolyn
- Leukotriene receptor antagonists: used to treat acute (monelukast and zafrlukast)
- AntilgE monoclonal antibody (omalizumab)



Chronic Obstructive Pulmonary Disease (COPD)

- It is a progressive disease characterized by chronic and recurrent obstruction (may be reversible) of airflow in the lungs.
 - Emphysema
 - Chronic obstructive bronchitis





COPD

1. Chronic obstructive bronchitis


It is an obstruction of the airways due to mucus hypersecretion and fibrosis of the bronchiolar wall which is associated with chronic irritation from smoking and recurrent infections.


2. Emphysema

Loss of lung elasticity and abnormal enlargement of the air spaces, with destruction of the alveolar walls and capillary beds.

Types

- Centriacinar emphysema
- Panacinar emphysema







Emphysema


Causes

- Smoking, main cause of emphysema
- **Deficiency of α1-antitrypsin**, an antiprotease enzyme












Emphysema

Symptoms





- Minimal cough, shortness of breath, dyspnea, recurrent respiratory infections
- Pink puffers: tachypnea
- Pursed-lip breathing
- Wheezing
- Barrel chest
- Respiratory failure: diaphragm fatigue




- Emphysema
- Diagnosis
 - Pulmonary functions: spirometer (TLC, VC, FVC, FEV1, FEV1/FVC ratio)
 - Chest radiography
 - Hemoglobin saturation, and arterial blood gases

VC: vital capacity, the maximum amount of air can be expelled from the lungs after a maximum inhalation (4L).

FVC: forced vital capacity, the volume of air that can forcibly be blown out after full inspiration (4.5-5L)

FEV1: forced expiratory volume in 1 second, the volume of air that can forcibly be blown out in first 1 second after full inspiration (80% of FVC)






Emphysema

- Treatment
- 1. Life style management: Stop Smoking
- 2. Pulmonary rehabilitation program
- 3. Oxygen therapy
- 4. Pharmacological medications
 - Bronchodilators: B2-agonists, anticholinergics

3. Cystic Fibrosis (CF)


- It is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, and GIT.
- Secretions become sticky and thick instead of acting as a lubricant.




3. Cystic Fibrosis (CF)

Causes

 a mutation in the gene cystic fibrosis transmembrane regulator (CFTR).






3. Cystic Fibrosis


Obstructive Lung Diseases

Symptoms



3. Cystic Fibrosis

Diagnosis



3. Cystic Fibrosis

Treatment

- Antibiotics
- Chest physical therapy (chest percussion and postural drainage)
- Mucolytic agents
- Nutritional therapy including pancreatic enzyme replacement

